Mitochondria are key organelles in eukaryotic cells and have been shown to be involved in a variety of biological activities such as energy production, cellular metabolism, ROS production, apoptosis, and redox reactions. Its dysfunction can lead to the development of a variety of diseases, including tumors. Many studies have confirmed that mitochondria are widely involved in various life activities of organisms, such as a variety of biometabolic activities including bone metabolism, as well as various programmed cell death processes and clock acceleration. However, the underlying mechanisms of mitochondrial dysfunction and disease progression have not been fully understood over the past decades. In addition, mitochondrial dysfunction is closely linked to chemoresistance and alterations in the immune microenvironment, leading to tumor escape as well as drug resistance. Therefore, targeting mitochondria to develop precise and personalized therapies for different diseases is particularly important.
With the advent of second-generation sequencing, single-cell sequencing, and spatial transcriptomics, the value of integrated multi-omics analyses in uncovering potential molecules involved in disease progression is becoming increasingly evident. By integrating multiple information on gene expression, cell populations, and specific spaces, multi-omics analyses will play a great role in identifying disease features and promoting precision therapies.
This Research Topic aims to provide a comprehensive and up-to-date collection of Original Research articles, Reviews, Mini-Reviews, Opinions, and Perspectives that utilize multi-omics to uncover the role of mitochondrial gene defects in disease progression.
We invite contributions from researchers working in the following areas:
1. Use of multi-omics to uncover key mitochondrial gene targets in disease;
2. Application of mitochondrial regulators in tumor and non-tumor diseases;
3. Prospects for clinical application of mitochondria-targeted drugs;
4. The importance of mitochondrial defects in tumor and non-tumor disease progression;
5. Prospects for the clinical application of mitochondrial regulators in combination with immunotherapy;
6. Prediction of targeted mitochondrial drugs using multi-omics.
Mitochondria are key organelles in eukaryotic cells and have been shown to be involved in a variety of biological activities such as energy production, cellular metabolism, ROS production, apoptosis, and redox reactions. Its dysfunction can lead to the development of a variety of diseases, including tumors. Many studies have confirmed that mitochondria are widely involved in various life activities of organisms, such as a variety of biometabolic activities including bone metabolism, as well as various programmed cell death processes and clock acceleration. However, the underlying mechanisms of mitochondrial dysfunction and disease progression have not been fully understood over the past decades. In addition, mitochondrial dysfunction is closely linked to chemoresistance and alterations in the immune microenvironment, leading to tumor escape as well as drug resistance. Therefore, targeting mitochondria to develop precise and personalized therapies for different diseases is particularly important.
With the advent of second-generation sequencing, single-cell sequencing, and spatial transcriptomics, the value of integrated multi-omics analyses in uncovering potential molecules involved in disease progression is becoming increasingly evident. By integrating multiple information on gene expression, cell populations, and specific spaces, multi-omics analyses will play a great role in identifying disease features and promoting precision therapies.
This Research Topic aims to provide a comprehensive and up-to-date collection of Original Research articles, Reviews, Mini-Reviews, Opinions, and Perspectives that utilize multi-omics to uncover the role of mitochondrial gene defects in disease progression.
We invite contributions from researchers working in the following areas:
1. Use of multi-omics to uncover key mitochondrial gene targets in disease;
2. Application of mitochondrial regulators in tumor and non-tumor diseases;
3. Prospects for clinical application of mitochondria-targeted drugs;
4. The importance of mitochondrial defects in tumor and non-tumor disease progression;
5. Prospects for the clinical application of mitochondrial regulators in combination with immunotherapy;
6. Prediction of targeted mitochondrial drugs using multi-omics.
